What They Actually Stole From Families

The parents who bought TruHeight products were not being careless. They were responding to what looked like clinical proof, real testimonials, and a community of other parents whose children had measurably grown. Every signal they trusted was manufactured.

Children were the product’s audience. Ads ran on Meta platforms showing kids at 4’7″ becoming 5’2″, teenagers going from 5’10” to 6’0″, a child documented at 4’1″ reaching 4’4″ after three months. Parents who bought the Max Height Kit at $120 a bundle were not buying a supplement; they were buying hope sold to them with invented evidence. That hope had a documented price tag and a fabricated foundation.

The FTC’s complaint documents that fake reviews were written specifically in the voice of parents describing their children’s bodies. One fabricated review described a doctor confirming improved bone health. The harm here is the calculated use of parental trust, and the medical language of childhood development, as a sales mechanism by employees who had never used the product.

In Their Own Words

“make sure to use VPN’s and different IP addresses to avoid facebook [sic] detection”

— Co-CEO Eden Stelmach, in an email to the bot contractor, copying Co-CEO Justin Rapoport. Source: FTC Complaint, Paragraph 22.

• This instruction was given by the company’s top executive to a third-party contractor specifically to help bot accounts evade platform safety systems. It proves deliberate circumvention of platform rules, not an oversight by a lower-level employee.
• The email was copied to both co-CEOs, establishing that this was a coordinated, executive-level decision.
• The explicit goal was to hide from Facebook that the social proof TruHeight displayed to prospective customers was generated by software, not real people.

“[w]e had almost 50 of the bots suspended last week and the bots are not sounding or looking like real people, they are being flagged by people as bots.”

— Co-CEO Eden Stelmach, in an email to the bot contractor, copying Co-CEO Justin Rapoport. Source: FTC Complaint, Paragraph 23.

• This is not a discovery of wrongdoing; it is troubleshooting wrongdoing. The CEO’s concern was operational performance of the fraud, not whether the fraud should continue.
• Real users on the platforms were already flagging the accounts as fake. The response from executive leadership was to improve the bots, not stop the program.

“Secondly, comments are being generated through ChatGPT. Which is the most cutting-edge natural language model out there. We can control the output through good prompts but there’s an upper limit to it. The ratio of comments generated which look like human responses is quite good; flagging only 15 comments out of 100.”

— Third-party contractor, in a response to Stelmach and Rapoport. Source: FTC Complaint, Paragraph 23.

• The contractor’s update confirms that AI-generated comments were being used to simulate real consumer enthusiasm for a health product targeted at children.
• The metric “15 comments out of 100 flagged” was presented as a success rate, meaning TruHeight accepted that 85% of its fake consumer activity was passing as real at the time.

“Better Bone Growth: I got these for my daughter because the doctor said her bone growth was stagnating. I was surprised that she enjoyed them, and since then, she grew about three inches in the last four months! Her doctor also mentioned her bone health was better than before”

— Fake review published on TruHeight’s website, written by a Vanilla Chip employee. Source: FTC Complaint, Paragraph 19.

• This review was written by a Vanilla Chip employee and published as a real consumer review. It was based on no actual product use and describes no real child.
• The review invoked a physician’s authority twice, fabricating the appearance of medical validation. It was specifically designed to reach parents whose children had documented growth concerns.
• This is not a marketing exaggeration. It is a fabricated medical testimonial targeting parents of children with documented health conditions.

What You Were Told vs. What Was True

TruHeight’s advertising rested on three documented false pillars: scientific proof, real consumer results, and an authentic community of satisfied users. All three were manufactured.

• TruHeight advertised its products as “THE ONLY SUPPLEMENT CLINICALLY PROVEN TO HELP HEIGHT GROWTH” and “SCIENTIFICALLY PROVEN TO HELP HEIGHT GROWTH.” The FTC found the company possessed no clinical evidence proving those products cause increased height in children or teenagers.
• The website displayed “Children’s Growth Pattern Study” statistics (86.66% saw height growth, 32.63% more growth than control group) to create the impression of rigorous scientific validation. The underlying study had 32 participants, lacked proper randomization, and failed to control for sleep and nutrition, making these figures misleading as proof of product efficacy.
• Thousands of five-star reviews on the TruHeight website were presented as authentic consumer experiences. Many were written by Vanilla Chip employees who had never used the products. The site also featured before/after photos and named testimonials that were displayed as organic customer responses.
• TruHeight operated approximately 176 bot social media accounts that posted comments on its Facebook and Instagram pages, impersonating real community members. Consumers who checked the brand’s social engagement as a signal of authenticity were looking at software output.

The Loopholes They Drove a Supplement Line Through

TruHeight operated across two structural gaps: the pre-existing absence of an FTC rule governing fake and incentivized reviews, and the dietary supplement industry’s general exemption from pre-market efficacy proof requirements.

• Dietary supplements are not required to prove efficacy to the FDA before sale. TruHeight’s products were classified as dietary supplements, which meant the company could sell height-growth claims to parents for years while the burden of disproving those claims fell to federal regulators, not to the company.
• The FTC’s Trade Regulation Rule on Consumer Reviews and Testimonials (16 C.F.R. Part 465) did not become effective until October 21, 2024. TruHeight’s “Free Next Order” incentivized review program ran from 2021 through 2022, and a co-CEO personally solicited paid-for reviews in April 2023, none of which fell under the new rule’s enforcement scope.
• The bot campaign was a violation of Facebook and Instagram’s platform policies, but platform policy violations are not federal law violations. TruHeight instructed its contractor to use VPNs and rotating IPs specifically to stay below the threshold of platform detection. The conduct was wrong under platform rules; the question of what federal law covered it was unresolved until the FTC acted.

Millions in Revenue. One Flawed Study. Zero Valid Proof.

TruHeight generated millions of dollars in revenue from products whose core health claim the FTC determined was false, built on a study the FTC identified as fundamentally insufficient.

• The company sold products continuously since at least 2020 at price points ranging from $25 to $120 per unit or bundle. The FTC documents “millions of dollars in revenue” from these sales.
• The sole scientific substantiation for the height-growth claims was a single company-sponsored study of 32 participants over six months. The FTC identified it as insufficient in size and duration, lacking proper randomization, and failing to control for two variables (sleep and nutritional intake) that directly affect children’s growth.
• Rather than commission valid research, Respondents instead built a review infrastructure. The company ran at least three parallel systems to manufacture social proof: employee-written fake reviews, cash/product incentives for five-star ratings, and an AI-powered bot network on social media.

Following the Letter While Violating the Purpose

TruHeight’s incentivized review program continued for over three years while operating in the gap between what existing law prohibited and what the FTC’s new Reviews and Testimonials Rule would eventually cover.

• The FTC Act prohibited deceptive practices broadly, but prior to October 21, 2024, there was no specific trade regulation rule codifying the prohibition on conditioning reviews on a particular sentiment. TruHeight’s “Free Next Order” program (2021-2022) and the co-CEO’s personal review solicitations (April 2023) predated the new rule and were charged under the general FTC Act, not the specific regulation.
• After the Reviews and Testimonials Rule took effect on October 21, 2024, TruHeight continued offering a 10% discount conditioned on leaving a five-star review with a photo. The complaint documents this continued “on numerous occasions after October 21, 2024,” establishing that the company had actual notice of the new rule and proceeded anyway.
• The dietary supplement framework designed to protect consumers from unevaluated drug claims requires disclaimers stating products “have not been evaluated by the Food and Drug Administration.” TruHeight’s ads carried these disclaimers in small print at the bottom while the large-print claim above read “CLINICALLY PROVEN.” The disclaimer’s presence did not make the efficacy claim honest.

Five Years of Sales Before Any Accountability

TruHeight sold products under false health claims for at least five years. The conduct continued even after the company received notice from federal regulators.

• TruHeight began selling products in at least 2020. The FTC’s complaint was prepared in 2025/2026, meaning consumers were exposed to false efficacy and fake reviews for the entire intervening period with no enforcement barrier.
• The incentivized review program ran from 2021 through at least November 2024. The bot network was engaged in May 2023 and was still operational as of the complaint. The company did not self-correct; it continued until federal investigation forced it to stop.
• The FTC issued a Civil Investigative Demand (CID). Only after receiving it did TruHeight represent, in December 2024, that it had removed consumer reviews from its website. The misconduct did not stop when it was discovered; it stopped when the company could no longer plausibly deny awareness of the investigation.

They Hired a Bot Farm and Called It Marketing

TruHeight did not build its own fake-identity infrastructure. It contracted that work to a third party, creating a layer of operational distance between the company’s executives and the direct execution of the fraud.

• In May 2023, Respondents engaged a third-party contractor to operate software-automated bot profiles on Facebook and Instagram. The contractor purchased 156 accounts from a vendor and created approximately 20 more in-house. The contractor’s work was contracted and paid for by Vanilla Chip.
• The contractor used ChatGPT to generate the comments posted by the bot accounts. The volume, tone, and targeting of those comments were directed by Vanilla Chip, which received detailed performance reports including a named list of all fake accounts and the volume of their interactions with TruHeight’s pages.
• Eden Stelmach directly instructed the contractor to use VPNs and rotating IPs to avoid platform detection. This instruction was issued from the CEO level, copying the co-CEO, showing the parent company controlled both the strategic direction and the operational security of the fraud.
• Despite the contractor’s operational role, liability in the FTC settlement falls on Vanilla Chip LLC, Stelmach, and Rapoport jointly and severally. The contractor is not named as a respondent in the FTC action.

Three Separate Machines for Faking Credibility

TruHeight did not rely on a single deceptive tactic. It built three parallel, coordinated systems to simulate the appearance of a product that worked and a consumer base that loved it.

• System one: employee-written reviews. Until at least November 2024, Vanilla Chip employees wrote fake five-star reviews posted to the company’s website as authentic consumer experiences, including fabricated accounts of children’s health improvements verified by doctors.
• System two: paid reviews. The “Free Next Order” program (2021-2022) and the subsequent 10% discount offer (December 2023 through at least November 2024) conditioned rewards on five-star ratings with photos. Co-CEO Rapoport personally solicited paid-for reviews in April 2023, offering reimbursement after confirmation of a five-star post.
• System three: bot social media accounts. Approximately 176 purchased Facebook and Instagram bot accounts posted ChatGPT-generated comments on TruHeight’s pages to simulate a real, engaged consumer community. The contractor was specifically instructed by the CEO to prevent platform detection.

Who Gets Hurt When Science Is Fake

Public Health

Economic Inequality

• Products were priced from $25 (individual items) to $120 (the Max Height Kit bundle). Families who purchased multiple products over months, as the testimonials depicted, spent hundreds of dollars on supplements with no proven efficacy. These were not trivial purchases for working families.
• The FTC entered a $4,000,000 liability figure, which the Commission identified as representing consumer injury. Even if every dollar of the $750,000 settlement payment is returned to consumers, that represents less than one dollar in nineteen of the documented harm, and only if the FTC pursues direct consumer redress rather than depositing funds to the Treasury.
• Lower-income families who encountered these products through Meta ads (the primary advertising channel documented in the complaint) and lacked access to health literacy resources to evaluate clinical claims were structurally more vulnerable to these deceptions.

The Families Paid. The Company Negotiated.

Every dollar TruHeight collected from families rested on a false foundation. The settlement structure documents that the financial harm to consumers substantially exceeds what will be returned to them.

• Consumers paid $25 to $120 per product unit or bundle. The FTC documents “millions of dollars in revenue” generated through these sales since at least 2020. The $4,000,000 liability figure represents the Commission’s assessment of consumer injury.
• Of the $4,000,000 liability, only $750,000 will be paid: $300,000 immediately, $225,000 at four months, and $225,000 at eight months after the order’s effective date. The remaining $3,250,000 is suspended based on the company’s claimed financial condition.
• The Decision and Order states that funds paid to the Commission “may be deposited into a fund administered by the Commission or its designee to be used for relief, including consumer redress.” The word “may” is operative. If direct redress is deemed “wholly or partially impracticable,” money can be used for other relief or deposited to the U.S. Treasury. Consumers who purchased TruHeight products have no guaranteed right to any portion of the $750,000.

$4 Million on Paper. $750,000 in Reality. No Admission of Wrongdoing.

The FTC’s consent order against TruHeight contains the mechanisms of accountability without its substance: a large liability number, a small actual payment, and no acknowledgment from the company that it did anything wrong.

• The consent agreement explicitly states that Respondents “neither admit nor deny any of the allegations in the Complaint, except as specifically stated in this Decision and Order.” The only things they admit are the jurisdictional facts necessary for the FTC to act. Every documented act of fraud in the complaint carries no admission of guilt.
• The $3,250,000 suspension is contingent on the truthfulness of financial statements the FTC is accepting from the respondents. The order states: “The Commission’s agreement to the suspension of part of the liability is expressly premised upon the truthfulness, accuracy, and completeness of Respondents’ sworn financial statements.” The FTC cannot independently verify those statements without further investigation.
• The gap between liability and payment ($3,250,000, calculated from the $4,000,000 entered against the $750,000 required: calculated from source figures) is larger than the total amount TruHeight must pay. A company that generated “millions of dollars in revenue” since 2020 by selling a fraudulent product is exiting this process having paid less than one-fifth of the assessed consumer harm.
• The order is binding for 20 years on representations and review practices. However, the financial penalty, as structured, provides minimal deterrence: the cost of compliance is a fraction of the revenue the misconduct generated.

The Architecture of Profitable Fraud

The TruHeight case is not an anomaly in how the supplement industry operates. It is a documented example of how existing structural gaps make this fraud model viable and how the penalty structure ensures it can remain profitable even after enforcement.

• The dietary supplement regulatory framework does not require pre-market proof of efficacy. A company can sell a height-growth supplement to parents of children for five years while the FTC builds its case. The enforcement burden sits with the government, not the seller.
• A consent order with no admission of wrongdoing and a suspended $3.25M liability creates no public record of fraud for corporate reputation purposes. TruHeight’s co-CEOs can operate future supplement companies under the 20-year compliance period while having never legally admitted to faking a single review.
• The FTC’s Reviews and Testimonials Rule (16 C.F.R. Part 465) was not effective until October 21, 2024. TruHeight ran its incentivized review program for at least three years before that rule existed. The rulemaking process itself, which began with an advance notice in November 2022, took approximately two years to finalize. Corporate conduct that is known and harmful can operate legally during the rulemaking window.

Structural Reforms This Case Demands

This case exposes three specific failure modes: pre-market efficacy standards that are absent for supplements, a review integrity enforcement framework that arrived years after the conduct it targets, and a penalty structure that makes fraud financially survivable.

The following are editorial recommendations based on the documented failure modes of this case. They are not findings of the source document.

Regulatory Track

• The FTC and FDA should jointly require dietary supplement companies making clinical efficacy claims to register those claims and their underlying studies in a public database before those claims appear in advertising. The TruHeight case demonstrates that a 32-person, company-sponsored study can anchor years of “clinically proven” advertising with no external check.
• The FTC’s Reviews and Testimonials Rule should include a mandatory pre-notification requirement for companies that operate review solicitation programs, similar to how sweepstakes require disclosure. The three-year gap between TruHeight’s “Free Next Order” program and the rule’s effective date should not be repeatable.
• Platform companies (Meta, Google, Amazon) should be required by regulation to share bot-account detection data with the FTC when a brand under investigation is identified. TruHeight’s contractor was working against both the platforms and consumers simultaneously.

Legislative Track

• Congress should amend the Dietary Supplement Health and Education Act (DSHEA) to require that any efficacy claim in supplement advertising be supported by at least one independent (non-company-sponsored) study meeting minimum standards for size, duration, randomization, and blinding before the claim can be published.
• Civil penalty authority for FTC Act violations in the supplement space should be strengthened. The current consent-order structure, which allows liability suspension and no admission of wrongdoing, provides insufficient deterrence for companies generating millions in revenue from false claims.
• Federal law should explicitly prohibit the use of automated software accounts (bots) to generate consumer reviews or testimonials for any commercial product, with per-account civil penalties sufficient to make bot-farm economics unprofitable.

Corporate Governance Track

• As a condition of the consent order, Vanilla Chip should be required to submit all future advertising claims to an independent scientific review board before publication, rather than self-certifying substantiation under the current order structure.
• Executive compensation at Vanilla Chip should be structurally decoupled from revenue targets during the compliance period, documented and certified annually to the FTC, to reduce the financial incentive for the same conduct under different branding.
• The 20-year compliance monitoring period should include mandatory annual independent audits of all consumer-facing review platforms and social media accounts associated with the Respondents, reported directly to the FTC’s Bureau of Consumer Protection.

Where to Direct Your Attention and Energy

The individuals who directed this conduct are Co-CEOs Eden Stelmach and Justin Rapoport of Vanilla Chip LLC, Las Vegas, NV. They have signed a 20-year consent order. They have admitted nothing.

• Watchlist: The Federal Trade Commission (FTC) Bureau of Consumer Protection is the primary enforcement body. Monitor ftc.gov for Vanilla Chip LLC compliance reports, which must be filed annually for the first year and are part of the public record.
• Watchlist: The Food and Drug Administration (FDA) regulates dietary supplement labeling. If TruHeight products return with new efficacy claims, those claims can be reported to the FDA’s MedWatch program and to the FTC at ReportFraud.ftc.gov.
• If you purchased TruHeight products, submit your purchase records to the FTC. The order requires Respondents to provide customer information to enable consumer redress. Your documentation strengthens the Commission’s ability to administer refunds.
• If you see supplement advertising claiming clinical proof of a health outcome, look for the study. Who funded it, how many participants, and whether it has been published in a peer-reviewed journal are the three questions this case proves you should be asking.
• Support the Dietary Supplement Safety Act and any legislative effort to close the DSHEA pre-market evidence gap. The gap that allowed TruHeight to operate is structural, and it remains open for the next company with a different product and the same playbook.